Gossamer Bio Inc (GOSS)

$0.35 -0.03 (-7.55%)
Market Cap 81.32M
Revenue (ttm) 48.47M
Net Income (ttm) -170.37M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -351.50%
Debt to Equity Ratio 0.00
Volume 9,487,000
Avg Vol 18,110,529
Day's Range N/A - N/A
Shares Out 234.70M
Stochastic %K 15%
Beta 2.08
Analysts Sell
Price Target $3.68

Company Profile

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercia...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 684 1300
Address:
3115 Merryfield Row, Suite 120, San Diego, United States
GlobalMarketBulletin
GlobalMarketBulletin Mar. 29 at 8:49 AM
$GOSS Gossamer Bio’s Phase 3 setback shocked investors—but Wall Street isn’t backing down. With analysts maintaining bullish ratings, GOSS may still hold hidden upside in the biotech space. https://globalmarketbulletin.com/heres-why-you-must-seriously-consider-investing-in-gossamer-bio-goss/
0 · Reply
GlobalMarketBulletin
GlobalMarketBulletin Mar. 29 at 8:28 AM
$DVLT $GOSS $JSPR $RCKT $EVTL These penny stocks are gaining attention for their explosive upside potential, with some analysts seeing 1000% gains ahead. Discover the opportunities—and risks—behind today’s most talked-about micro-cap stocks. https://globalmarketbulletin.com/top-10-penny-stocks-that-could-turn-1000-into-1-million/
0 · Reply
justthenib
justthenib Mar. 28 at 3:33 PM
$GOSS
0 · Reply
Love_whams
Love_whams Mar. 28 at 10:51 AM
$GOSS i think they will 0 - reverse split🤩 1- dump it hard to shake the weak 2 - pump it hard then dump the 200 million shares 👍 3 - limp mode it 4 - fraudulent bankrupt the company 5 - there is no other way 😎🤣 enjoy your weekend babes ❤️😘
1 · Reply
Love_whams
Love_whams Mar. 28 at 10:47 AM
$GOSS for me if it drops its a win as more to add✅if it goes up its a win🥇looking like a win either way just DONT forget they applied for 200 million shares to DUMP when ever they like😲🤯
0 · Reply
Gmblr777
Gmblr777 Mar. 27 at 8:55 PM
$GOSS what is this +25% spike
1 · Reply
justthenib
justthenib Mar. 27 at 7:43 PM
$GOSS
0 · Reply
justthenib
justthenib Mar. 27 at 7:38 PM
$GOSS betting on Bobby
0 · Reply
Gmblr777
Gmblr777 Mar. 27 at 11:28 AM
$GOSS another red day in market 🤦🏻
0 · Reply
redbeamgold
redbeamgold Mar. 27 at 9:31 AM
$GOSS what’s the option scene today? That will probably tell us what the move is. Or perhaps it’s burn Shorty day!
0 · Reply
Latest News on GOSS
Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

Mar 17, 2026, 4:01 PM EDT - 11 days ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q1

Mar 5, 2026, 6:16 AM EST - 24 days ago

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q1

BWAY DH

GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm

Mar 1, 2026, 4:07 PM EST - 27 days ago

GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm

Gossamer Bio, Inc. (GOSS) Discusses Topline Results of PROSERA Phase 3 Study in Pulmonary Arterial Hypertension Transcript

Feb 23, 2026, 4:25 PM EST - 4 weeks ago

Gossamer Bio, Inc. (GOSS) Discusses Topline Results of PROSERA Phase 3 Study in Pulmonary Arterial Hypertension Transcript

BREAKING: Gossamer Bio Investors Should Contact Block & Leviton to Potentially Recover Losses After Shares Fall Over 75%

Feb 23, 2026, 12:40 PM EST - 4 weeks ago

BREAKING: Gossamer Bio Investors Should Contact Block & Leviton to Potentially Recover Losses After Shares Fall Over 75%

Gossamer Bio Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses

Feb 23, 2026, 11:26 AM EST - 4 weeks ago

Gossamer Bio Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses

Gossamer Bio Plans FDA Talks After Narrow Miss In Key Pivotal Study, Stock Sinks

Feb 23, 2026, 9:57 AM EST - 4 weeks ago

Gossamer Bio Plans FDA Talks After Narrow Miss In Key Pivotal Study, Stock Sinks

Gossamer Bio's experimental lung condition drug fails in late-stage trial

Feb 23, 2026, 8:11 AM EST - 4 weeks ago

Gossamer Bio's experimental lung condition drug fails in late-stage trial

Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension

Feb 23, 2026, 8:00 AM EST - 4 weeks ago

Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 8, 2026, 5:30 PM EST - 2 months ago

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio to Participate in Upcoming Investor Conferences

Nov 24, 2025, 4:01 PM EST - 4 months ago

Gossamer Bio to Participate in Upcoming Investor Conferences

Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 4:01 PM EST - 5 months ago

Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update

Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital

Sep 25, 2025, 7:41 AM EDT - 6 months ago

Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital

Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension

Sep 25, 2025, 7:31 AM EDT - 6 months ago

Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension

Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025

Sep 22, 2025, 7:31 AM EDT - 6 months ago

Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025

Gossamer Bio: Bullish Ahead Of Seralutinib's Phase 3 Readout

Sep 9, 2025, 9:50 AM EDT - 7 months ago

Gossamer Bio: Bullish Ahead Of Seralutinib's Phase 3 Readout

Gossamer Bio to Present at Upcoming Investor Conferences

Aug 29, 2025, 7:31 AM EDT - 7 months ago

Gossamer Bio to Present at Upcoming Investor Conferences

Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 5, 2025, 4:01 PM EDT - 8 months ago

Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update

Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH

Jun 16, 2025, 7:31 AM EDT - 10 months ago

Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH

Gossamer Bio, Inc. (GOSS) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 9:30 PM EDT - 11 months ago

Gossamer Bio, Inc. (GOSS) Q1 2025 Earnings Conference Call Transcript

Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

May 15, 2025, 4:01 PM EDT - 11 months ago

Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025

May 12, 2025, 4:01 PM EDT - 11 months ago

Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025

Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference

May 7, 2025, 4:01 PM EDT - 11 months ago

Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference

Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Mar 13, 2025, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD

Feb 13, 2025, 7:42 PM EST - 1 year ago

Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD

Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Feb 3, 2025, 7:01 AM EST - 1 year ago

Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Jan 28, 2025, 7:01 AM EST - 1 year ago

Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 4:03 PM EST - 1 year ago

Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update

Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss

Sep 10, 2024, 1:25 AM EDT - 1 year ago

Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss

Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024

Aug 26, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Aug 20, 2024, 7:00 AM EDT - 1 year ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA CVKD ELUT EUDA GDTC GOVX IMRN

Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says

Jun 25, 2024, 2:39 PM EDT - 1 year ago

Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

May 14, 2024, 4:01 PM EDT - 2 years ago

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024, 4:01 PM EDT - 2 years ago

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment

May 6, 2024, 7:46 AM EDT - 2 years ago

Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications

May 6, 2024, 7:30 AM EDT - 2 years ago

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications

Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine

May 3, 2024, 8:02 AM EDT - 2 years ago

Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D.

Mar 12, 2024, 7:31 AM EDT - 2 years ago

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D.

Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Mar 5, 2024, 7:31 AM EST - 2 years ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023

Dec 13, 2023, 4:01 PM EST - 2 years ago

Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023

Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

Dec 5, 2023, 7:01 AM EST - 2 years ago

Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

GlobalMarketBulletin
GlobalMarketBulletin Mar. 29 at 8:49 AM
$GOSS Gossamer Bio’s Phase 3 setback shocked investors—but Wall Street isn’t backing down. With analysts maintaining bullish ratings, GOSS may still hold hidden upside in the biotech space. https://globalmarketbulletin.com/heres-why-you-must-seriously-consider-investing-in-gossamer-bio-goss/
0 · Reply
GlobalMarketBulletin
GlobalMarketBulletin Mar. 29 at 8:28 AM
$DVLT $GOSS $JSPR $RCKT $EVTL These penny stocks are gaining attention for their explosive upside potential, with some analysts seeing 1000% gains ahead. Discover the opportunities—and risks—behind today’s most talked-about micro-cap stocks. https://globalmarketbulletin.com/top-10-penny-stocks-that-could-turn-1000-into-1-million/
0 · Reply
justthenib
justthenib Mar. 28 at 3:33 PM
$GOSS
0 · Reply
Love_whams
Love_whams Mar. 28 at 10:51 AM
$GOSS i think they will 0 - reverse split🤩 1- dump it hard to shake the weak 2 - pump it hard then dump the 200 million shares 👍 3 - limp mode it 4 - fraudulent bankrupt the company 5 - there is no other way 😎🤣 enjoy your weekend babes ❤️😘
1 · Reply
Love_whams
Love_whams Mar. 28 at 10:47 AM
$GOSS for me if it drops its a win as more to add✅if it goes up its a win🥇looking like a win either way just DONT forget they applied for 200 million shares to DUMP when ever they like😲🤯
0 · Reply
Gmblr777
Gmblr777 Mar. 27 at 8:55 PM
$GOSS what is this +25% spike
1 · Reply
justthenib
justthenib Mar. 27 at 7:43 PM
$GOSS
0 · Reply
justthenib
justthenib Mar. 27 at 7:38 PM
$GOSS betting on Bobby
0 · Reply
Gmblr777
Gmblr777 Mar. 27 at 11:28 AM
$GOSS another red day in market 🤦🏻
0 · Reply
redbeamgold
redbeamgold Mar. 27 at 9:31 AM
$GOSS what’s the option scene today? That will probably tell us what the move is. Or perhaps it’s burn Shorty day!
0 · Reply
Gmblr777
Gmblr777 Mar. 26 at 9:53 PM
$GOSS looks like impossible to reach 1$ again 🫠
1 · Reply
Sinimini
Sinimini Mar. 26 at 9:02 PM
$GOSS 2 USD soon
1 · Reply
Cheaslea76
Cheaslea76 Mar. 26 at 8:31 PM
$GOSS
0 · Reply
Gmblr777
Gmblr777 Mar. 26 at 7:48 PM
$GOSS almost green when market dumped 2%+ Bottom?
0 · Reply
Bullishontherize
Bullishontherize Mar. 26 at 6:55 PM
$GOSS
0 · Reply
Bullishontherize
Bullishontherize Mar. 26 at 6:11 PM
$GOSS Yes. The shorts are buying lots of borrow fees.
0 · Reply
Gmblr777
Gmblr777 Mar. 26 at 5:47 PM
$GOSS anyone buying?
0 · Reply
Hahaha111
Hahaha111 Mar. 26 at 1:45 PM
$GOSS squeeze???
0 · Reply
Racerock98
Racerock98 Mar. 26 at 10:02 AM
$GOSS Heading to $0.50
0 · Reply
Cheaslea76
Cheaslea76 Mar. 26 at 8:28 AM
$GOSS
0 · Reply
Bullishontherize
Bullishontherize Mar. 26 at 12:29 AM
$GOSS greedy piggies get slaughtered...
0 · Reply
SnoopDawg
SnoopDawg Mar. 25 at 7:44 PM
$GOSS 2 reasons its up. Rezolute false positive explained to fda and fda says ok go ahead and get us detailed data for our documentation and apply we understand. Similar situation w false positive here with one clinical site throwing the trial with several outliers in control group. Also tax loss wash periods expiring so major repositioning coming back in.
3 · Reply